Company reports Q2 2026 revenue of $109 million and adjusted EBITDA near $50 million as part of growth strategy.
Pacira BioSciences announced a 2026 revenue guidance range of $735 million to $760 million, reflecting confidence in its 5×30 growth strategy. The company cited strong commercial execution and pipeline progress as key drivers behind the target.
In Q2 2026, Pacira reported revenue exceeding $109 million and adjusted EBITDA of nearly $50 million. The company also highlighted expansion efforts, targeting 160 million covered lives for its EXPAREL product.
Management attributed the performance to disciplined execution, cash generation, and strategic partnerships, reinforcing long-term growth objectives.